IAPP and type 2 diabetes mellitus: Two monoclonal antibodies (mAbs) are reported that bind human islet amyloid polypeptide (hIAPP) protofibrils and inhibit their aggregation and toxicity to pancreatic islets in a mouse model of rapidly progressing type 2 diabetes mellitus (T2D).